SUTENT is an inhibitor of multiple receptor tyrosine kinases (TKIs), including the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), which are expressed in many types of solid tumours and are thought to play a crucial role in angiogenesis.1
Dysregulation of the VEGF pathway is frequently associated with RCC, due to loss of function of the von Hippel-Lindau gene2 making mRCC a highly vascular tumour and underlying why the VEGF pathway continues to be a target in RCC.2
Watch the mechanism of action video for SUTENT
In 2006:
Today:
Motzer RJ, et al. Lancet Oncol 2019;20:1370–1385
Gore ME, et al. Br J Cancer 2015;113:12–19
Noize P, et al. Pharmacoepidemiol Drug Saf 2017;26:1561–1569.
Ruiz-Morales J, et al. Eur J Cancer 2016;65:102–108.
Lalani A, et al. Can Urol Assoc J 2017;11:112–117.
Motzer RJ, et al. J Clin Oncol 2009;27:3584–3590.
Motzer RJ, et al. N Engl J Med 2013;369:722–731.
Motzer RJ, et al. 2009.
Gore ME, et al. 2015.
Ruiz-Morales JM, et al. 2016.
Noize P, et al. 2017.
Lalani AA, et al. 2017.
Data taken from Motzer RJ, et al. 2009. Gore ME, et al. 2015. Ruiz-Morales JM, et al. 2016. Noize P, et al. 2017. Lalani AA, et al. 2017.
EAP, Expanded Access Programme. IMDC, International Metastatic Renal Cell Carcinoma Database Consortium. OS, overall survival. No cross-trial comparisons may be made since trials were conducted using different methodologies and at different time points. Final and investigator review analyses unless otherwise stated.
*Clinical trial data.†Data for MSKCC risk groups. ‡Data for IMDC risk groups
See all SUTENT Safety Information
AE : Adverse Event
ESMO: European Society for Medical Oncology
IMDC : International Metastatic RCC Database Consortium
IO : Immuno-Oncology
mOS : Median Overall Survival
mPFS : Median Progression-Free Survival
mRCC : Metastatic Renal Cell Carcinoma
NHS : National Health Service
NICE : National Institute for Health and Care Excellence
OS : Overall Survival
PFS : Progression-Free Survival
TKI : Tyrosine Kinase Inhibitor
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021